JP2013535508A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535508A5
JP2013535508A5 JP2013524253A JP2013524253A JP2013535508A5 JP 2013535508 A5 JP2013535508 A5 JP 2013535508A5 JP 2013524253 A JP2013524253 A JP 2013524253A JP 2013524253 A JP2013524253 A JP 2013524253A JP 2013535508 A5 JP2013535508 A5 JP 2013535508A5
Authority
JP
Japan
Prior art keywords
antigen
cancer
tumor
virus
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013524253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535508A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/047633 external-priority patent/WO2012021834A1/en
Publication of JP2013535508A publication Critical patent/JP2013535508A/ja
Publication of JP2013535508A5 publication Critical patent/JP2013535508A5/ja
Pending legal-status Critical Current

Links

JP2013524253A 2010-08-13 2011-08-12 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント Pending JP2013535508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37376310P 2010-08-13 2010-08-13
US61/373,763 2010-08-13
PCT/US2011/047633 WO2012021834A1 (en) 2010-08-13 2011-08-12 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Publications (2)

Publication Number Publication Date
JP2013535508A JP2013535508A (ja) 2013-09-12
JP2013535508A5 true JP2013535508A5 (cg-RX-API-DMAC7.html) 2014-09-25

Family

ID=45564978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524253A Pending JP2013535508A (ja) 2010-08-13 2011-08-12 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント

Country Status (14)

Country Link
US (1) US20120039916A1 (cg-RX-API-DMAC7.html)
EP (1) EP2603235A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013535508A (cg-RX-API-DMAC7.html)
KR (1) KR20130108295A (cg-RX-API-DMAC7.html)
CN (1) CN103328005A (cg-RX-API-DMAC7.html)
AR (1) AR082686A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011289234B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013002940A2 (cg-RX-API-DMAC7.html)
CA (1) CA2807585A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013001527A (cg-RX-API-DMAC7.html)
RU (1) RU2013110889A (cg-RX-API-DMAC7.html)
TW (1) TWI506035B (cg-RX-API-DMAC7.html)
WO (1) WO2012021834A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301013B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
ES2846400T3 (es) * 2007-05-03 2021-07-28 Agency For Science Tech And Research Astarstar Anticuerpos que se unen a un polipéptido PRL-1 o PRL-3 intracelular
WO2012122396A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
AR088220A1 (es) 2011-08-29 2014-05-21 Baylor Res Inst Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma
WO2013134293A1 (en) * 2012-03-05 2013-09-12 Duke University Vaccine formulation
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
WO2015035173A1 (en) * 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
AU2015209277B2 (en) * 2014-01-22 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
AU2015258875B2 (en) 2014-05-16 2020-12-24 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
CN106456736A (zh) * 2014-06-02 2017-02-22 贝勒研究院 用于治疗过敏和炎性疾病的方法和组合物
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
JP6760919B2 (ja) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド 腫瘍を治療するための抗pd−l1組み合わせ
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN104689313A (zh) * 2015-03-04 2015-06-10 中国科学院海洋研究所 大菱鲆cd83分子作为疫苗佐剂的应用
US10624964B2 (en) 2015-05-01 2020-04-21 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN116510015A (zh) * 2015-11-10 2023-08-01 耶鲁大学 用于治疗自身免疫疾病和癌症的组合物及方法
KR20180124014A (ko) 2015-12-15 2018-11-20 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) Ebv-세포 항원 및 표적화 모이어티를 포함하는 면역원성 컨스트럭트 및 그의 응용
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
AU2017228474C1 (en) 2016-03-04 2024-03-28 Abmuno Therapeutics Llc Antibodies to TIGIT
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
EP3645043A4 (en) * 2017-06-28 2021-04-07 The Board of Trustees of the Leland Stanford Junior University METHODS AND COMPOSITIONS FOR DECTIN 2 STIMULATION AND CANCER IMMUNOTHERAPY
CA3083231A1 (en) * 2017-11-29 2019-06-06 Adaptive Phage Therapeutics, Inc. Methods of vaccination using icosahedral phage
SG11202008291XA (en) * 2018-02-28 2020-09-29 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
JP7670614B2 (ja) * 2019-01-22 2025-04-30 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗原提示好中球由来樹状細胞およびその使用方法
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220004985A (ko) 2019-03-27 2022-01-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd40 활성화 특성을 가진 재조합 단백질
US20220298255A1 (en) * 2019-05-31 2022-09-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
KR20220131895A (ko) * 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
JP2023525140A (ja) 2020-05-13 2023-06-14 アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) Ox40活性化特性を有する組換えタンパク質
CA3184802A1 (en) 2020-05-26 2021-12-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
EP4157875A1 (en) 2020-06-02 2023-04-05 Arcus Biosciences, Inc. Antibodies to tigit
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ,インク. 抗asgr1抗体コンジュゲートおよびその使用
CN111850006B (zh) * 2020-07-27 2022-04-22 齐鲁工业大学 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用
US20240010739A1 (en) 2020-11-12 2024-01-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
IL302874A (en) * 2020-11-18 2023-07-01 Pionyr Immunotherapeutics Inc Anti-Marco antibodies and their uses
KR20230124672A (ko) 2020-12-23 2023-08-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항원 제시 세포에 대한 momp vs4 항원의 표적화에 기반한클라미디아 백신
MX2023008986A (es) 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
WO2023081806A2 (en) * 2021-11-04 2023-05-11 The General Hospital Corporation Anti-mesothelin antibody reagents
MX2024006003A (es) 2021-11-17 2024-08-06 Inst Nat Sante Rech Med Vacunas universales contra el sarbecovirus.
KR20250080855A (ko) 2022-10-05 2025-06-05 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 니파바이러스 감염에 대한 dc 표적 백신
EP4601682A1 (en) * 2022-10-13 2025-08-20 The Brigham & Women's Hospital, Inc. Methods and compositions for improving response to immunotherapy
KR102878250B1 (ko) * 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물
WO2024216189A1 (en) * 2023-04-13 2024-10-17 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057915C (zh) * 1994-09-19 2000-11-01 中国医学科学院医药生物技术研究所 免疫佐剂
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
MX2009008140A (es) * 2007-02-02 2009-10-26 Baylor Res Inst Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
CA2717659C (en) * 2007-02-23 2017-08-22 Baylor Research Institute Therapeutic applications of activation of human antigen-presenting cells through dectin-1
DK2224954T3 (en) * 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
WO2010009346A2 (en) * 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
JP5883653B2 (ja) * 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートBaylor Research Institute 抗原提示細胞ターゲティング抗ウイルスワクチン
CN108373509A (zh) * 2009-03-10 2018-08-07 贝勒研究院 靶向抗原呈递细胞的抗病毒疫苗
CA2754862C (en) * 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
CA2798616A1 (en) * 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells

Similar Documents

Publication Publication Date Title
JP2013535508A5 (cg-RX-API-DMAC7.html)
RU2013110889A (ru) Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
RU2012152828A (ru) Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека
US20120231023A1 (en) Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
TWI423985B (zh) 利用dectin-1活化人類抗原呈現細胞之醫療應用
JP6952029B2 (ja) T細胞療法用のt細胞を調製する方法
TWI446921B (zh) 基於表現於抗原-表現細胞之樹突細胞免疫受體(dcir)之標的抗原之疫苗
WO2004027049B1 (en) Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells
TW200846370A (en) Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
JP2015071598A5 (cg-RX-API-DMAC7.html)
JP2017508797A (ja) Tエフェクター細胞の調節性t細胞に対する比を増加するための方法および組成物
JP2001524928A (ja) クロスプライミング免疫による天然抗原に特異性を有するctlの誘導
Cohen et al. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens
CN113797332B (zh) 用于免疫疗法的组合物和方法
Jemon et al. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy
Gamat-Huber et al. Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Sokke Umeshappa et al. CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination
WO2024246364A1 (en) Combination containing an mrna vaccine or an mrna encoded therapeutic protein and an immune modulating mrna for improved or reduced immunogenicity to increase efficacy
Park Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo
JP2023539525A (ja) 抗体療法
JP2025531191A (ja) ナチュラルキラーt細胞リガンドおよび抗原を負荷した末梢血単核細胞を含むワクチン
EP4146701A1 (en) Fusion proteins for immunotherapy against cancer and infectious diseases
Li et al. A Novel Antigen Delivery System for Cancer Immunotherapy Using Antigens Linked to Inactivated Salmonella Bacteria
RU2420311C2 (ru) Вакцина на основе в-клеток, нагруженных лигандом т-клеток-природных киллеров и антигеном
CN116891828A (zh) 新型的免疫刺激分子及改造的外泌体及其制备方法和应用